Close this search box.



  • Bendelac, A., Savage, P. B., and Teyton, L. (2007) The Biology of NKT Cells. Annu. Rev. Immunol25, 297–336.
  • Boes, M. (2000) Role of natural and immune IgM antibodies in immune responses. Mol. Immunol. 37, 1141–1149.
  • Boland, C. R., and Ricciardiello, L. (1999) How many mutations does it take to make a tumor ? Proc. Natl. Acad. Sci. U. S. A. 96, 14675–14677.
  • Cohn, M., Av Mitchison, N., Paul, W. E., Silverstein, A. M., Talmage, D. W., and Weigert, M. (2007) Reflections on the clonal-selection theory. Nat Rev Immunol 7, 823–830.
  • Doria-Rose, N. A., and Joyce, M. G. (2015) Strategies to guide the antibody affinity maturation process. Curr. Opin. Virol. 11, 137–147.
  • Freeman, S. A., Jaumouillé, V., Choi, K., Hsu, B. E., Wong, H. S., Abraham, L., Graves, M. L., Coombs, D., Roskelley, C. D., Das, R., Grinstein, S., and Gold, M. R. (2015) Toll-like receptor ligands sensitize B-cell receptor signalling by reducing actin-dependent spatial confinement of the receptor. Nat. Commun. 6, 6168.
  • Groscurth, P., and Filgueira, L. (1998) Killing Mechanisms of Cytotoxic T Lymphocytes. Physiology 13, 17–21.
  • Kurts, C., Robinson, B. W. S., and Knolle, P. A. (2010) Cross-priming in health and disease. Nat. Publ. Gr. 10, 403–414.
  • Iwasaki, A., and Medzhitov, R. (2010) Regulation of Adaptive Immunity by the Innate Immune System. Science 327, 291 LP-295.
  • Nimmerjahn, F., and Ravetch, J. V. (2008) Fcγ receptors as regulators of immune responses. Nat Rev Immunol 8, 34–47.
  • Rickert, R. C. (2005) Regulation of B lymphocyte activation by complement C3 and the B cell coreceptor complex. Curr. Opin. Immunol17, 237–243.
  • Rosenberg, S. A., and Restifo, N. P. (2015) Adoptive cell transfer as personalized immunotherapy for human cancer. Science348, 62–68.
  • Stumbles, P. A., Himbeck, R., Frelinger, J. A., Collins, E. J., Lake, R. A., and Robinson, B. W. S. (2004) Cutting Edge : Tumor-Specific CTL Are Constitutively Cross-Armed in Draining Lymph Nodes and Transiently Disseminate to Mediate Tumor Regression following Systemic CD40 Activation. J. Immunol. 173, 5923–5928.